Cornea, Gingival Diseases, Skin Diseases
Conditions
Keywords
biomechanics, cornea, skin, gingiva, optical coherence tomography, vibrography
Brief summary
The overall goal of this study is to develop OCT Vibrography (aka OCT elastography) as a novel tool for measuring biomechanical properties of human tissues in vivo.
Detailed description
The overall goal of this study is to develop OCT Vibrography (aka OCT elastography) as a novel tool for measuring biomechanical properties of human tissues in vivo. The investigators aim to establish baseline data in healthy subjects, compare elastic moduli in different tissue types, and measure differences in elastic moduli between keratoconus and normal eyes. If successful, this project will provide useful, previously inaccessible elastic parameters and advance the investigators' understanding of the relationship between the bulk mechanical properties and the microstructure of the human tissue in vivo. This information can ultimately be used to improve the diagnosis and treatment of keratoconus, inflammatory skin diseases, and inflammatory gingiva diseases. More broadly, the technologies developed in this project will have relevance to other potential applications beyond the tissues in this research study.
Interventions
OCT vibrography
Sponsors
Study design
Eligibility
Inclusion criteria
Group 1: Inclusion criteria: • Subjects with healthy eyes (age 18 - 75, N = 50)
Exclusion criteria
* Subjects with history of eye diseases, and previous eye surgeries. * Subjects with diabetes, glaucoma family history * Subjects allergic to anesthetic eyedrop, especially proparacaine * Subjects with severe allergy * Subjects who have difficulty biting * Subjects who have recurrent corneal erosion Group 2: Inclusion criteria: • Subjects with healthy skin (age 18 - 75, N = 10)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects to successfully complete OCT Vibrography without serious unanticipated adverse events related to application of the device. | 1 year | Frequency and severity of all treatment-related adverse events |
Countries
United States
Contacts
Massachusetts General Hospital